Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC)

中部地区

• 批准号: 104232
• 金额: $ 1099.46万
• 依托单位: UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104232
• 关键词: Midlands; Wales; Advanced; Therapy; Treatment

"ATMPs, which can be _cell or gene therapies_, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are **major challenges in rolling them out to patients**. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a **team of industrialists, clinicians, academics and computer system experts** who have all the necessary skills to succeed in this project.Our group **covers the Midlands and Wales** giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.We will:-Set up a network of hospitals with medical staff trained to receive and administer ATMPs.-Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.-Put in place the IT systems to manage the end-to-end process.-Validate this new infrastructure using real ATMPs-Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.-Set-up protocols to test whether the **cost of a new ATMP is justified by its clinical effectiveness.**The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field."

“ATMP可以是细胞或基因疗法，在治疗目前治疗无法治愈的患者方面显示出巨大的潜力。这些疾病包括关节炎、肝病、几种癌症和糖尿病溃疡。ATMP刚刚开始上市，英国发挥了主导作用。然而，即使新的ATMP疗法被开发出来并被证明是有效的，在向患者推广时也存在 ** 重大挑战 **。其原因包括：运输“活”产品的复杂性，以及大多数NHS医院对此类产品缺乏了解。该项目由伯明翰生物医学研究中心牵头，该中心是国家卓越中心。威尔士政府也对细胞疗法进行了重大投资，并支持NHS威尔士作为该项目的联合领导者。我们是一个由工业家，临床医生，学者和计算机系统专家组成的团队，他们拥有在这个项目中取得成功所需的所有技能。我们的团队覆盖了中部地区和威尔士地区，使我们能够接触到主要的教学医院和近1500万人，为细胞疗法的成功提供了一个独特的机会。我们将：-建立一个医院网络，并培训医务人员接受和管理ATMP。-建立无缝供应链，确保“活药”在从生产实验室转移到床边时保持健康和有效。建立IT系统来管理端到端流程。使用真实的ATMP构建新的基础设施-提供一个使用此基础设施加快临床试验中ATMP测试的程序。建立协议，以测试新ATMP的 ** 成本是否符合其临床有效性。** MW-ATTC的好处是（a）患有挑战性疾病的患者将获得突破性药物;（B）ATMP公司将进入临床主流和市场;（c）对这一重要行业的投资将增加，因为我们证明英国是ATMP研发的绝佳地点。MW-ATTC将成为英国三大先进治疗中心之一，为患者和ATMP创新者共同努力，以巩固英国在这一重要领域的世界领导者地位。"